Payment overview · 2025
General Payments
$151.04
9 reported records · 6 companies
Healthcare provider profile · identity verified
Eric David Harding, MD
Allopathic & Osteopathic Physicians|Internal Medicine · NEW ALBANY, MS · NPI 1942203286
Verified facts
What the public records show
CMS Open Payments records show Eric David Harding, MD received $151.04 in general payments during 2025 across 9 reported records.
GlaxoSmithKline, LLC. accounted for 30.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Linzess by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $45.28 | 30.0% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $34.68 | 23.0% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $19.23 | 12.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.65 | 12.3% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $16.79 | 11.1% | 1 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.41 | 10.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $151.04 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $45.28 | 3 | 2025 |
Source payment records
|
|||||
| PEDIARIX Normalized: pediarix |
Biological | GlaxoSmithKline, LLC. | $45.28 | 3 | 2025 |
Source payment records
|
|||||
| ROTARIX Normalized: rotarix |
Biological | GlaxoSmithKline, LLC. | $30.81 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $19.85 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $19.85 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $19.23 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $19.23 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $19.23 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $18.65 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $18.65 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $18.65 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $16.79 | 1 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $16.41 | 1 | 2025 |
Source payment records
|
|||||
| PENMENVY Normalized: penmenvy |
Biological | GlaxoSmithKline, LLC. | $14.47 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 28 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
48 | 48 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
107 | 101 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
82 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
28 | 28 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
97 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 494 | 132 |
| Atorvastatin Calcium | Atorvastatin Calcium | 460 | 139 |
| Gabapentin | Gabapentin | 311 | 72 |
| Carvedilol | Carvedilol | 309 | 82 |
| Losartan Potassium | Losartan Potassium | 269 | 81 |
| Levothyroxine Sodium | Levothyroxine Sodium | 229 | 55 |
| Pantoprazole Sodium | Pantoprazole Sodium | 224 | 68 |
| Metoprolol Succinate | Metoprolol Succinate | 217 | 60 |
| Potassium Chloride | Potassium Chloride | 213 | 51 |
| Furosemide | Furosemide | 203 | 51 |
| Trazodone Hcl | Trazodone Hcl | 200 | 45 |
| Omeprazole | Omeprazole | 199 | 59 |
| Hydrochlorothiazide | Hydrochlorothiazide | 197 | 47 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 190 | 54 |
| Metformin Hcl | Metformin Hcl | 160 | 50 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 138 | 46 |
| Lisinopril | Lisinopril | 124 | 39 |
| Montelukast Sodium | Montelukast Sodium | 121 | 33 |
| Sertraline Hcl | Sertraline Hcl | 116 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 114 | 32 |
| Meloxicam | Meloxicam | 113 | 37 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 107 | 101 |
| Fluticasone Propionate | Fluticasone Propionate | 106 | 39 |
| Spironolactone | Spironolactone | 101 | 28 |
| Eliquis | Apixaban | 97 | 20 |
| Amitriptyline Hcl | Amitriptyline Hcl | 96 | 31 |
| Duloxetine Hcl | Duloxetine Hcl | 90 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 89 | 32 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 89 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 88 | 18 |
| Famotidine | Famotidine | 85 | 30 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 82 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 80 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 78 | 25 |
| Ropinirole Hcl | Ropinirole Hcl | 73 | 19 |
| Lovastatin | Lovastatin | 72 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 72 | 13 |
| Allopurinol | Allopurinol | 69 | 21 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 64 | 64 |
| Simvastatin | Simvastatin | 63 | 15 |
| Alendronate Sodium | Alendronate Sodium | 61 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 61 | 14 |
| Glimepiride | Glimepiride | 54 | 13 |
| Ozempic | Semaglutide | 51 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 48 | 48 |
| Fluconazole | Fluconazole | 44 | 14 |
| Bupropion Xl | Bupropion Hcl | 42 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 42 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 41 | 14 |
| Divalproex Sodium | Divalproex Sodium | 41 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 41 | 12 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 41 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 38 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 37 | suppressed |
| Ezetimibe | Ezetimibe | 37 | 11 |
| Metformin Hcl Er | Metformin Hcl | 36 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 35 | 11 |
| Chlorthalidone | Chlorthalidone | 34 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 34 | 30 |
| Meclizine Hcl | Meclizine Hcl | 34 | 16 |
| Dicyclomine Hcl | Dicyclomine Hcl | 33 | suppressed |
| Pregabalin | Pregabalin | 33 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 32 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 15 |
| Donepezil Hcl | Donepezil Hcl | 31 | 13 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 30 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 30 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 30 | suppressed |
| Prednisone | Prednisone | 30 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 29 | suppressed |
| Torsemide | Torsemide | 29 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 28 | 28 |
| Irbesartan | Irbesartan | 28 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 28 | suppressed |
| Jardiance | Empagliflozin | 27 | suppressed |
| Memantine Hcl | Memantine Hcl | 27 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 26 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | suppressed |
| Finasteride | Finasteride | 24 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Trulicity | Dulaglutide | 24 | suppressed |
| Valsartan | Valsartan | 24 | suppressed |
| Linzess | Linaclotide | 23 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 23 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 22 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 22 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 21 | suppressed |
| Ondansetron Odt | Ondansetron | 21 | 11 |
| Atenolol | Atenolol | 20 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Primidone | Primidone | 19 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 19 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 18 | suppressed |
| Digoxin | Digoxin | 18 | suppressed |
| Estradiol | Estradiol | 18 | suppressed |
| Methocarbamol | Methocarbamol | 18 | suppressed |
| Nystatin | Nystatin | 18 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Mounjaro | Tirzepatide | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Sotalol | Sotalol Hcl | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Januvia | Sitagliptin Phosphate | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Cefdinir | Cefdinir | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Nexium | Esomeprazole Magnesium | 11 | suppressed |
| Ofev | Nintedanib Esylate | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | 11 |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $151.04 · 9 records | GlaxoSmithKline, LLC. | ABRYSVO, BEXSERO, CAPVAXIVE, COMIRNATY, GARDASIL 9, OTEZLA, PEDIARIX, PENMENVY, PREVNAR 20, QULIPTA, Qelbree, REPATHA, ROTARIX, VAXNEUVANCE | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error